Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
Authors
Keywords
-
Journal
Journal of Immunology Research
Volume 2018, Issue -, Pages 1-11
Publisher
Hindawi Limited
Online
2018-10-16
DOI
10.1155/2018/4263520
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens
- (2017) Jinjing Xu et al. Expert Review of Anticancer Therapy
- EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer
- (2017) Yang Li et al. International Journal of Nanomedicine
- Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers
- (2017) Chengcheng Zhang et al. MOLECULAR THERAPY
- Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
- (2017) Akash Patnaik et al. Cancer Discovery
- Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis
- (2017) Wei Xia Ang et al. Oncotarget
- Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
- (2017) Qing Zhang et al. Journal of Immunology Research
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
- (2017) Kristen M. Hege et al. Journal for ImmunoTherapy of Cancer
- Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
- (2017) Irene Scarfò et al. Journal for ImmunoTherapy of Cancer
- Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma
- (2016) Hidehiko Takigawa et al. CANCER SCIENCE
- Global patterns and trends in colorectal cancer incidence and mortality
- (2016) Melina Arnold et al. GUT
- Regorafenib induced severe toxic hepatitis: characterization and discussion
- (2016) Anne Sacré et al. LIVER INTERNATIONAL
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
- (2016) Richard P. Junghans et al. PROSTATE
- Mechanisms of drug resistance in colon cancer and its therapeutic strategies
- (2016) Tao Hu et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity
- (2015) Yanhong Wu et al. BMC CANCER
- Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM
- (2015) Zhenling Deng et al. BMC IMMUNOLOGY
- Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias
- (2015) Gabriella Pietra et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
- (2015) Hung Huynh et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice
- (2015) Fei-Ting Hsu et al. Oncotarget
- An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer
- (2015) Mei-Ying Liao et al. Oncotarget
- Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
- (2015) Estelle Daudigeos-Dubus et al. PLoS One
- CD8+T cell–specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors
- (2014) Jiemiao Hu et al. Molecular Cancer
- A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma
- (2014) Hirokazu Matsushita et al. Journal for ImmunoTherapy of Cancer
- Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer
- (2013) D. Alizadeh et al. CANCER RESEARCH
- A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA
- (2013) Huiwen Hao et al. CELL BIOLOGY INTERNATIONAL
- Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer
- (2013) Y. Homma et al. Clinical & Translational Oncology
- Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma
- (2012) Roniel Cabrera et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer
- (2012) Stephanie K. Bunt et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
- (2012) Christiane Sahm et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Improved Activation toward Primary Colorectal Cancer Cells by Antigen-Specific Targeting Autologous Cytokine-Induced Killer Cells
- (2012) Claudia Schlimper et al. Clinical & Developmental Immunology
- Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
- (2012) K. Tamada et al. CLINICAL CANCER RESEARCH
- Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM
- (2012) Naoto Shirasu et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response
- (2011) Akitaka Takahara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma
- (2011) Antonia Busse et al. EUROPEAN JOURNAL OF CANCER
- Use of allogeneic NK cells for cancer immunotherapy
- (2011) Melissa A Geller et al. Immunotherapy
- Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging
- (2010) Reinhard Meier et al. MAGNETIC RESONANCE IN MEDICINE
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
- (2008) Martin A Pule et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now